Alpine Immune Sciences raises $91M in private placement led by Frazier to fund ALPN-303 phase 1 and ALPN-202 cancer trials
Alpine Immune Sciences raised about $91 million via a private placement led by Frazier Healthcare Partners to advance ALPN-303 into a phase 1 study for lupus and other inflammatory diseases and to support ongoing cancer trials of ALPN-202, including a combination study with Merck's Keytruda.
No comments yet.